Live Breaking News & Updates on Valor Hcm

Stay updated with breaking news from Valor hcm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Clinical Trial Outcomes for Cardiac Myosin Inhibitors in oHCM Treatment

An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM. ....

Jamesl Januzzi , Clinical Trial Outcomes , Cardiac Myosin Inhibitors , Ohcm Treatment , Obstructive Hypertrophic Cardiomyopathy , Peak V02 , Rejection Fraction , Good Monitoring , Explorer Hcm , Valor Hcm , Septal Reduction Therapy ,

Dr Milind Desai on VALOR-HCM: Primary and Secondary Effects Are Sustained While on Mavacamten

Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic. ....

Milind Desai , York Heart Association , Vascular Thoracic Institute , Hypertrophic Cardiomyopathy Center , New York Heart Association , Thoracic Institute , Cleveland Clinic , Kansas City Questionnaire , Valor Hcm ,

Dr Milind Desai Highlights New Findings From VALOR-HCM Trial

After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic. ....

Milind Desai , Hypertrophic Cardiomyopathy Center , European Society Of Cardiology , Vascular Thoracic Institute , Thoracic Institute , Cleveland Clinic , European Society , Valor Hcm , Explorer Hcm ,